Health-Related Quality Of Life (Hrqol) Of Pembrolizumab Plus Chemotherapy Versus Chemotherapy As First-Line Therapy In Patients With Advanced Esophageal Cancer: The Phase Iii Keynote-590 Study.

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 5|浏览24

暂无评分

摘要

168Background: In the randomized, international, double-blind, placebo-controlled KEYNOTE-590 (NCT03189719) study, pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant a...

查看译文

关键词

Pembrolizumab,Chemotherapy,Oncology,Medicine,Advanced esophageal cancer,First line therapy,Health related quality of life,In patient,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要